Natera Inc (NTRA) carries a ŷRobot AI score of 36 out of 100. The model's fair value estimate is $281.45, 32.1% below the last close of $414.52. The chart signal reads Sell.
| Metric | NTRA |
|---|---|
| AI score | 36 / 100 |
| Chart signal | Sell |
| Fair value estimate | $281.45 |
| Upside to fair value | -32.1% |
| Previous close | $414.52 |
| P/E | -245.77 |
| Price / sales | 17.14 |
| Market cap | $59.47B |
| EPS | -1.31 |
| Revenue growth | 34.4% |
| 1-year price change | 31.4% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
As of Sep 30, 2026, ŷRobot's fair-value model estimates Natera Inc (NTRA) at $281.45 against a last close of $414.52, implying 32.1% downside to the model's estimate.
The chart-signal model classifies NTRA as Neutral as of Sep 30, 2026, with a signal score of -0.15 on a -1 to 1 scale.
NTRA scores 36 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Sep 30, 2026.
NTRA trades at -245.8 times earnings and 17.1 times sales as of Sep 30, 2026.
ŷRobot's seasonal forecast curve for NTRA reads -1.2% at 30 days, +2.4% at 90 days, and +31.4% at one year as of Sep 30, 2026. Seasonal tendencies are historical patterns, not predictions.
Natera Inc's revenue growth is +34.4% and free-cash-flow growth is -43.6% on the latest reported figures.
NTRA chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.